Psychedelic-Assisted Therapy in Australia: How the Authorised Pathway Works

This guide is strictly informational. Nothing here is medical advice, and nothing here should be read as promoting or endorsing any specific treatment, provider, or outcome — Australian law prohibits advertising prescription-only medicines to the public, and we take that seriously in how this page is written.

What the Authorised Prescriber pathway actually is

Since 1 July 2023, Australia’s Therapeutic Goods Administration has permitted two specific substances — psilocybin (for treatment-resistant depression) and MDMA (for PTSD) — to be prescribed, but only by psychiatrists individually approved under the TGA’s Authorised Prescriber (AP) scheme. This is not a general prescribing pathway: an eligible psychiatrist must be an individually approved specialist, gain Human Research Ethics Committee approval, develop a clinical treatment protocol aligned with published research and a TGA checklist, and submit six-monthly patient-treatment reports to retain their authorisation.

Outside this scheme, both substances remain unapproved therapeutic goods in Australia. GPs cannot prescribe either, and there is no walk-in or self-referral pathway — access is exclusively through an Authorised Prescriber psychiatrist’s clinical assessment.

What changed in 2026

A regulatory update — reported around July 2026 — relaxed the previous requirement that the authorised psychiatrist be physically present for the entire dosing session. A session can now proceed with a single AHPRA-registered health practitioner (a psychologist, GP, mental health nurse, or occupational therapist, for example) in the room, alongside a second staff member, and treatment is no longer restricted to hospital settings. This was reportedly intended to improve access for people in regional, rural, and First Nations communities, who have historically had limited access to the small number of clinics offering this treatment.

What treatment actually involves

Based on the Australian clinics we’ve reviewed for this directory, treatment is not a single session — it’s a structured, multi-month protocol combining psychotherapy, psychiatric assessment, one or more full-day dosing sessions under supervision, and follow-up integration support. This is a materially different model from a group retreat: individual, clinically supervised, and specific to the two approved conditions rather than general wellbeing.

Where to find factual information on providers

We list Australian clinical services offering this pathway in our clinics directory, in a deliberately restrained “neutral mode” — name, location, service category, and a contact link only, with no pricing, descriptions, or promotional content, consistent with TGA advertising rules around prescription-only medicines. We are not affiliated with any listed provider and receive no referral fees.